Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.58 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3756242 | 0.88 | ALDH1A1 (0.55) | LMNAALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL10989857 | 0.87 | LMNA (0.57) | LMNAALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL13543275 | 0.84 | ALDH1A1 (0.55) | LMNAALDH1A1KMT2AMEN1GAA | |
| SCHEMBL3920308 | 0.83 | LMNA (0.68) | LMNAALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL10984175 | 0.82 | NPSR1 (0.48) | ALDH1A1KMT2AMEN1GAAPOLB | |
| SCHEMBL13543499 | 0.82 | CYP3A4 (0.52) | LMNAALDH1A1KMT2AGAANPSR1 | |
| SCHEMBL4717296 | 0.82 | LMNA (0.51) | LMNAALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL10989432 | 0.81 | ATM (0.67) | LMNAALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL16000121 | 0.80 | ALDH1A1 (0.69) | LMNAALDH1A1KMT2A | |
| SCHEMBL9796338 | 0.80 | NPSR1 (0.49) | ALDH1A1KMT2AMEN1TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7595314-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595314-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595314-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090192136-A1 | BENZOYL-PIPERAZINE DERIVATIVES | ALBERATI-GIANI DANIELA | 2009-07-30 | — | — | US | disclosed |
| US-20090192136-A1 | BENZOYL-PIPERAZINE DERIVATIVES | ALBERATI-GIANI DANIELA | 2009-07-30 | — | — | US | disclosed |
| US-20090192136-A1 | BENZOYL-PIPERAZINE DERIVATIVES | ALBERATI-GIANI DANIELA | 2009-07-30 | — | — | US | disclosed |
| US-20090053172-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | AQUINO CHRISTOPHER JOSEPH | 2009-02-26 | — | — | US | disclosed |
| US-7452992-B2 | inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS); 1-((1R,5S)-8-{2-[3-(2,2-dimethylpropanoyl)-6-phenyl-1,3-oxazinan-6-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1663232-A1 | 1-(2-AMINO-BENZOYL)-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| US-20060052595-A1 | Heterocyclic compounds as ccr5 antagonists | SMITHKLINE BEECHAM CORPORATION | 2006-03-09 | — | — | US | disclosed |
| EP-1569931-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20050070539-A1 | Benzoyl-piperazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2005-03-31 | — | — | US | disclosed |
| WO-2005023260-A1 | 1- (2-AMINO-BENZOL) -PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023260-A1 | 1- (2-AMINO-BENZOL) -PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| WO-2004055011-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| US-4505913-A | Substituted anthranilamides and pharmaceutical preparations containing these compounds | CIBA-GEIGY CORPORATION (US) | 1985-03-19 | — | — | US | disclosed |
| EP-0008072-B1 | SUBSTITUTED ANTHRANILIC ACID AMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PREPARATION | CIBA-GEIGY AG (CH) | 1984-02-22 | — | — | EP | disclosed |
| EP-0008072-A1 | Substituted anthranilic acid amides, process for their preparation, pharmaceutical compositions containing them and their preparation | CIBA-GEIGY AG (CH) | 1980-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053172-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR1 | LMNA 4259/4885ALDH1A1 2775/4885KMT2A 4579/4885 |
| US-20060052595-A1 | Heterocyclic compounds as ccr5 antagonists | CCR5, CXCR3, CCR1 | LMNA 4259/4885ALDH1A1 2775/4885KMT2A 4579/4885 |
| US-20050070539-A1 | Benzoyl-piperazine derivatives | OPRL1, ACHE, PNMT | LMNA 4692/4885ALDH1A1 582/4885KMT2A 456/4885 |
| US-20090192136-A1 | BENZOYL-PIPERAZINE DERIVATIVES | OPRL1, ACHE, PNMT | LMNA 4692/4885ALDH1A1 582/4885KMT2A 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.